However, when ERK activation is inhibited by KRASG12C inhibitors, EGFR signaling acts as the dominant mechanism of colorectal cancer resistance to KRASG12C inhibitors (Amodio et al., 2020). This evidence concerns the gene EGFR and colorectal cancer.